<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A94912B-5896-4DB6-A946-8197453813A4"><gtr:id>3A94912B-5896-4DB6-A946-8197453813A4</gtr:id><gtr:name>Fluorogenics Limited</gtr:name><gtr:address><gtr:line1>17 LANCASTER ROAD , SARUM BUSINESS PARK</gtr:line1><gtr:city>SALISBURY</gtr:city><gtr:postCode>SP4 6FB</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A94912B-5896-4DB6-A946-8197453813A4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>3A94912B-5896-4DB6-A946-8197453813A4</gtr:id><gtr:name>Fluorogenics Limited</gtr:name><gtr:address><gtr:line1>17 LANCASTER ROAD , SARUM BUSINESS PARK</gtr:line1><gtr:city>SALISBURY</gtr:city><gtr:postCode>SP4 6FB</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>5000.0</gtr:offerGrant><gtr:projectCost>5000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A232E354-7155-42BE-94EA-947529415055"><gtr:id>A232E354-7155-42BE-94EA-947529415055</gtr:id><gtr:firstName>Grants</gtr:firstName><gtr:surname>Team</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=751536"><gtr:id>B4764305-9D03-4E20-BFE9-F1A370609A90</gtr:id><gtr:title>FGL Assurance Audits</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Vouchers</gtr:grantCategory><gtr:grantReference>751536</gtr:grantReference><gtr:abstractText>Fluorogenics Ltd (FGL) manufactures lyophilised products for nucleic acid amplification including PCR and isothermal methods that have unique patented formulations and properties. FGL will engage a quality assurance advisor to help design and audit its quality management system towards certification of ISO 13485:2012. This will increase its transition to manufacturing of human in vitro diagnostics increasing our market access and overseas trade. It will also allow FGL to self-certify its own IVDs.</gtr:abstractText><gtr:fund><gtr:end>2015-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>5000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">751536</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>